Update on the management of atrial fibrillation: Anticoagulation and medical therapy

Research output: Contribution to journalArticle

Abstract

2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck &Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future.

Original languageEnglish (US)
Pages (from-to)387-393
Number of pages7
JournalCurrent Cardiology Reports
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2011

    Fingerprint

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Dabigatran
  • Dronedarone
  • Medical therapy
  • Vernakalant

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this